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Summary The levels of serum ,B2 microglobulin, blood urea concentration, serum creatinine, haemoglobin
and performance status have been measured in 476 patients in the Medical Research Council's 4th trial for
myelomatosis. Levels of serum ,B2 microglobulin were also subsequently measured in 208 patients who
achieved a stable "plateau" condition. Serum ,B2 microglobulin levels, uncorrected for serum creatinine, were
found to be the single most powerful prognostic variable available at presentation. Multivariate analysis
showed that only the addition of haemoglobin levels could improve upon this and the improvement, though
statistically significant (P=0.006), appeared to be of much less clinical value. The prognostic value of serum
/B2 microglobulin at plateau appeared to be equally large for a given difference in value, but the variability
between patients was much less at that time. Serum /2 microglobulin would appear to be a key measurement
for assessing the prognosis and response to treatment in patients with myelomatosis.
There have been a large number of papers on
prognostic factors for myelomatosis and at least two
grouping systems (Durie & Salmon, 1975; Medical
Research Council, 1980) using multiple factors have
been devised. These studies indicate that the two
most important presenting factors influencing
survival in myelomatosis are measures of renal
function such as serum urea or creatinine and the
haemoglobin level. More recently a number of
reports have demonstrated that serum levels of f2
microglobulin are also important in predicting the
survival of patients with myelomatosis (Norfolk et
al., 1980, Child et al., 1983, Bataille et al., 1984). P2
microglobulin is a small protein (Mol. wt 11,800)
that forms the common chain of the class I major
histocompatibility complex on the cell surface
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(Cresswell et al., 1974). The role of f2 micro-
globulin in the broader context of immunology and
immunopathology has been reviewed recently by
Messner (1984). In disease the serum levels of,2-
microglobulin are influenced by two main factors,
the production rate and its clearance from the
blood by glomerular filtration; both factors can be
abnormal coincidentally or independently in
myelomatosis.
Previous studies have been performed on
relatively small numbers of patients and further
information on the relationship of,2 microglobulin
and previously identified prognostic factors is
desirable. Bataille et al. (1984) have discussed the
relationship between serum #2 microglobulin and
the staging system devised by Durie & Salmon
(1975), and Child et al. (1983) have done a more
complete multivariate analysis, but this was based
on only 64 patients. Also the value of followup
measurements has not been assessed on large
numbers ofpatients.
The major prognostic variables have been
measured on a large proportion of patients in the
Medical Research Council's 4th trial on myeloma-
tosis and the combined value of these variables
have been assessed in this paper.
Patients and methods
This analysis is based on the 476 patients out of
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530 randomised patients in the MRC's 4th trial for
myelomatosis for whom presentation measurement
of all of the following variables were available:
haemoglobin, blood urea concentration, serum
creatinine, performance status, and serum P2
microglobulin (s-#2m). The trial began in March
1980 and follow-up time ranged from 23 to 47
months (median 35 months). Details of the trial
and the treatment arms are reported elsewhere
(Medical Research Council, 1984 and in
preparation, 1985). A total of 268 patients
subsequently achieved a stable "plateau" condition.
Until 1st October 1983 patients were randomised to
stop active cytotoxic therapy after 6 months on
plateau or to receive a further year's treatment. The
level of s-,B2m was measured at this time on 208 of
the 226 patients randomized at plateau and its
predictive value on further follow-up has been
studied.
The s-fl2m levels at presentation were measured
in duplicate by a radioimmunoassay using the
Phadebas 42-micro test 100 supplied by Pharmacia
Diagnostics AB, Uppsala, Sweden. Measurements of
s-#2m on the plateau follow-up samples were made
by radial immunodiffusion using a goat antihuman
f2m antiserum purchased from Atlantic Antibodies.
The relationship between the radioimmunoassay (x)
and the radial immunodiffusion method (y) -
determined on 108 samples is given by the
equation:
y= 1.01x+0.8
and the correlation coefficient was 0.989.
Results
The performance of the major prognostic factors,
considered separately, are shown in Table I. The
largest x2 values (and hence greatest predictive
power) were obtained from the uncorrected s-f2m
values (X2=58.2, P<0.0001). The differences are
illustrated graphically in Figure 1. We found the
correction factor for renal failure recommended
by Cassuto et al. (1978) to be inaccurate and
unnecessarily complicated. Study of 50 individuals
with non-neoplastic conditions who were attending
hospital for renal disease and who possessed varying
degrees of renal failure indicated that a simple
linear relationship on a log-log scale between serum
creatinine and s-fl2m was adequate (R2 =0.95).
The estimated regression line was
log10(s-fl2m) = -1.77+ 1.15log10(s-creat)
where s-fl2m was measured in mgI1-I and creatinine
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Figure 1 Survival probabilities for patients according
to uncorrected presentation values of serum fl2-
microglobulin. Numbers in parentheses indicate
numbers of patients in each group. X2(trend)=58.2;
P<0.0001.
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Figure 2 Serum ,B2-microglobulin vs serum creatinine
in 50 patients without neoplastic disease. Both
variables are plotted on a logarithmic scale.
in mM (Figure 2). This simple correction is of a
similar form to that originally proposed by
Revillard & Vincent (1978) who obtained
log10(s-fl2m) -0.29+0.81 log10 (s-creat)
(where creatinine is expressed in mg 100ml-1).
Corrected s-f,2m levels were computed by
subtracting this value from the observed levels. This
led to negative values in some cases, as would be
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Table I Survival according to the major prognostic factors
Variable Levels N 0 OIE
s-,B2m
uncorrected
<4mglP
4-5.9
6-9.9
10-19.9
>20
144
94
128
57
53
64
51
86
40
42
X2=58.21 P<0.0001
x2 (in patients with creatinine <130mM) = 10.41 P=0.001
x2 (in patients with creatinine >130mM)=24.15 P<0.001
s-,B2m <Omgl-' 155 77
corrected (see text) 0-1.9 140 83
2-3.9 65 41
4-5.9 48 29
>6 68 53
X2=22.69, P<0.0001
x2 (in patients with creatinine <130mM)=9.48, P=0.002
X2 (in patients with creatinine >130mM) = 11.97, P=0.000.
Prognostic
groups
(see MRC 1980)
X2=36.05, P<0.0001
Blood urea
concentration
,2=36.31, P<0.0001
Serum creatinine
X2=32.53, P<0.0001
Haemoglobin
good
intermediate
poor
<8mM
8-14.9
>15
< 130mM
130-199
>200
<75gl
75-99
>100
111
267
98
317
99
60
278
109
89
61
124
291
44
170
69
171
67
45
147
71
65
43
92
148
0.61
0.84
1.17
1.54
2.42
0.77
0.92
1.12
1.07
1.85
5
0.54
1.06
1.67
0.82
1.27
2.11
0.80
1.10
1.88
1.69
1.48
0.76
x2=35.84, P<0.0001
The table gives numbers of patients (N), numbers of deaths (0),
and the observed-to-expected ratio (OIE) for each level of each
factor. A x2 for trend across levels (1do) is also given.
expected since the corrected value gives the excess
over that which would be expected in a normal
population and statistical fluctuations imply this
will be negative some of the time. These corrected
levels were found to be much less predictive of
survival than the uncorrected values (X2 =22.69,
Table I). The other major prognostic factors, e.g.
blood urea (or serum creatinine), haemoglobin, and
the composite prognostic groups based on urea,
haemoglobin and performance status (Medical
Research Council, 1980) were also much less
predictive than s-fl2m (Table I). These classical
factors all had about the same x2 (trend) values,
but of them, the prognostic grouping was probably
the most useful, because of the more even splitting
of the patients into different groups.
The prognostic value of s-,B2m was seen in all
three prognostic groups (Table II), and in fact was
most apparent in the good and intermediate
prognostic groups (x2= 13.30, P=0.0003 and
X2= 12.38, P=0.0004, respectively).
Some effect was also seen in the poor prognosis
group (X2 =4.81, P =0.03).
Longer term predictive value
It has previously been observed (Buckman et al.,
1982; Medical Research Council, 1984) that
prognostic variables in myelomatosis, especially
those related to renal function, are of less
prognostic value in long term follow-up than in the
period immediately after diagnosis. The x2 trend4 J. CUZICK et al.
Table II The predictive value of s-,B2m for survival in
different prognostic groups
Good prognosis patients N 0 OIE
Level <4mgl-' 63 21 0.77
4-5.9 31 11 0.93
6-9.9 11 7 1.94
10-19.9 5 4 3.47
>20 1 1 18.08
x2 (trend) = 13.30, P =0.0003
Intermediate prognosis patients
Level <4mgl-' 74 39 0.70
4-5.9 58 37 0.97
6-9.9 87 61 1.14
10-19.9 29 18 1.16
>20 19 15 2.07
x2 (trend)= 12.38, P=0.0004
Poor prognosis patients
Level <4mgl'- 7 4 0.70
4-5.9 5 3 0.77
6-9.9 30 18 0.72
10-19.9 23 18 1.13
>20 33 26 1.40
x2 (trend) =4.81, P=0.03
Adjusted summary x2 (trend) =24.80, P<0.0001
Table III The predictive value of various presenting
features for survival in the lVth Myelomatosis trial
x2 (trend) X2 (trend) patients
all surviving at least
Feature patients 1 year
Blood urea 36.31 4.12
Serum creatinine 32.53 3.92
Haemoglobin 35.84 7.22
Prognostic group 36.05 5.07
s-fl2m (uncorrected) 58.21 8.00
s-,B2m (corrected) 22.69 4.31
values are shown for prediction of survival after 1
year in all patients who survived that long in Table
III. Uncorrected s-,B2m (X2 =8.00, P=0.005) and
haemoglobin (X2=7.22, P=0.007) are seen to be the
most important predictors.
Follow-up measurements ofs-,B2m
Of the 268 patients achieving a stable plateau phase
in their disease, a total of 226 were re-randomized
for maintenance therapy. Two hundred and eight
had s-fl2m measured at the time of the second
randomization. The value of this measurement in
determining subsequent survival is shown in Table
IV and Figure 3. The follow-up samples were
analysed both as absolute levels and as a
percentage of the presentation level. The absolute
levels were predictive of subsequent survival
(X2=11.35, P=0.0008) whereas the percentage fall
conveyed no prognostic information (X2 =0.79,
P=0.4).
Table IV Prognostic value of s-,B2m level taken at
"plateau" phase
Variable Levels N 0 OIE
s-,B2m <3mgl-1 37 9 0.53
uncorrected
(at plateau) 3-3.9 81 30 0.94
4-4.9 34 11 0.88
>5 56 25 1.83
x2=ll.35, P=0.0008
ratio of s-,B2m <60% 48 15 0.86
at plateau to
presentation level 60-100% 77 26 0.96
> 100% 79 32 1.12
x2=0.79, P=0.4
Abbreviations are as in Table I.
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Figure 3 Survival probabilities according to
uncorrected levels of serum f2-microglobulin measured
at plateau phase in 208 patients who achieved this
condition. Numbers in parentheses indicate numbers
ofpatients in each group. X2(trend) = 12.52; P=0.0004.
The levels were generally less varied than at
presentation and the number of patients and
follow-up time was less than for presentation
analyses so that it is not possible to compare x2
values to judge the relative usefulness of the follow-
up measurement compared to the presentationSERUM ,B2M IN MYELOMATOSIS 5
Table V Summary of the multivariate analysis
Standard
Variable Coefficient error x2 (to remove)
Model I log(s-,B2m) 1.366 0.166 62.06
log(s-fl2m) 1.156 0.186 36.01
haemoglobin -0.0072 0.0026 7.50
Model II
log(s. creat) x2 to enter= 2.81
performance status x2 to enter=2.86
log(s-,B2m)
Model III at plateau 2.179 0.536 13.03
(N=208)
sample. However the regression coefficient attached
to log(s-fl2m) is not significantly different in the
presentation and follow-up samples (z= 1.45,
P=0.15) (Table V, Model III).
Multivariate analysis
The relative merits of s-#2m, creatinine,
haemoglobin and performance status were studied
by means of a stepwise proportional hazards
regression model. The levels of s-/32m and
creatinine were put on a logarithmic scale (base 10),
haemoglobin levels were on a linear scale, and
performance status was coded as a dichotomy:
asymptomatic or minimal symptoms vs restricted
activity or bedridden. The results are summarized
in Table V. Levels of s-fl2m clearly emerge as the
most important prognostic factor and are highly
significant in the univariate model (Model I,
2=62.06, P<0.0001). The regression coefficient for
log(S-f2m) was 1.366 suggesting that a doubling of
S-#2m leads to a 50% increase in the rate of death.
The only other variable which provided additional
information was haemoglobin (Model II, X2 =7.50,
P=0.006). Although clearly statistically significant,
this improvement would not appear to be
sufficiently great to be clinically helpful, and our
data suggest that measured s-f,2m levels alone are
likely to be enough to predict the prognosis in the
majority of patients. The estimated predictor of
prognosis took the form
1.156log(s-#2m(mg1-1)) 0.007Hb(g1 1)
with large values implying a poorer prognosis. The
median value was 0.13 and the upper and lower
quartiles were 0.50 and -0.23 respectively.
Discussion
The earliest studies of the levels of s-,B2m in benign
and malignant disease found that s-,B2m was
frequently raised in myelomatosis (Evrin & Wibell,
1973, Shuster et al., 1976, Kin et al., 1977). Norfolk
et al. (1980) reported that in 37 patients the
pretreatment level of s-#2m was an important
prognostic factor. They took 4mg1-1 as a
discriminant level and found that patients
presenting with a s-#2m >4mgI1 had a median
survival of 6 months, and those <4mgl-1 had a
median survival of 15 months. They confirmed the
earlier observations by a survey of 156 patients and
drew attention to the combined influences of a
raised s-fl2m due to renal insufficiency and hyper-
production. Revillard & Vincent (1976, 1978)
observed a simple linear relationship on a logarithmic
scale between serum creatinine and s-f2m in
patients with non-neoplastic conditions. Cassuto
et al. (1978) devised a polynomial equation to correct
for the GFR and observed that in myelomatosis
s-#2m levels were increased in patients with a
high tumour mass. Several investigators (Bataille
et al., 1982, 1984, Scarffe et al., 1983) have used
Cassuto's correction when examining the relationship
between s-,B2m and prognosis in myelomatosis.
Others have reported the prognostic value of the
uncorrected s-,B2m level and have shown that it
provides information which was not obtainable
from previously recognized prognostic factors (Child
et al., 1983; Bataille et al., 1983).
Sequential measurements of s-,B2m have been
reported to carry prognostic information (Child et
al., 1983, Bataille et al., 1984). Bataille et al. (1984)
observed s-#2m levels closely correlated with the6 J. CUZICK et al.
chemotherapy response in 70 out of 80 patients and
was comparable with the assessment of response
based on change of paraprotein level. Norfolk et al.
(1980), Child et al. (1983), Bataille et al. (1984) and
Garewal et al. (1984) have observed that the
plateau phase of the disease is associated with
s-fl2m levels that tend to stabilize, usually below
6mg -1. The terminal events in myelomatosis have
been observed to be associated with an upswing in
the levels of s-#2m (Norfolk et al., 1980, Bataille et
al., 1984).
Our studies confirm these observations, both at
initial diagnosis and during follow-up. We have
found that the presentation level of serum ,B2
microglobulin is the single most important
prognostic variable currently available. The
uncorrected values are more predictive than the
corrected ones, probably because they include a
contribution due to renal failure, as assessed by
elevated serum creatinine which itself has a negative
influence on survival. Little further information
appears to be available from simple measurements
of renal function, but haemoglobin levels do
provide some further independent prognostic
information. It should be noted, however, that
special attention was paid to management of renal
failure in the trial analysed in this paper. Patients in
this trial presenting in renal failure fared better
than equivalent patients in earlier trials (Medical
Research Council, 1984).
The variability of s-,B2m at follow-up is much
less than at presentation, but the prognostic
significance of specific levels appears to be similar
to that at presentation. We are encouraged by our
findings in patients assessed when in plateau phase
and by reports in the literature that sequential s-
fl2m levels can be used to monitor the disease
(Norfolk et al., 1980; Bataille et al., 1984).
Regularly repeated measurements of s-,B2m during
follow-up are included in the Medical Research
Council's current (fifth) trial. Our objective is to
relate the rate of change of s-fi2m to the evolution
of the disease and to investigate its value as an
indicator ofresponse to treatment.
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